The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These “first-in-class” treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.
Author(s): Wolf H. Fridman, Jérome Galon (auth.), Glenn Dranoff (eds.)
Series: Current Topics in Microbiology and Immunology 344
Edition: 1
Publisher: Springer-Verlag Berlin Heidelberg
Year: 2011
Language: English
Pages: 306
Tags: Cancer Research; Immunology
Front Matter....Pages i-xiii
Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control....Pages 1-24
Subversion and Coercion: The Art of Redirecting Tumor Immune Surveillance....Pages 25-39
STAT3: A Target to Enhance Antitumor Immune Response....Pages 41-59
Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology....Pages 61-95
Concepts and Ways to Amplify the Antitumor Immune Response....Pages 97-128
Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin....Pages 129-148
Adoptive Cellular Therapy....Pages 149-172
Dendritic Cell Subsets as Vectors and Targets for Improved Cancer Therapy....Pages 173-192
Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma....Pages 193-210
Modulation of CTLA-4 and GITR for Cancer Immunotherapy....Pages 211-244
Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways....Pages 245-267
LAG-3 in Cancer Immunotherapy....Pages 269-278
Immunologically Active Biomaterials for Cancer Therapy....Pages 279-297
Erratum to: Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma....Pages 299-299
Back Matter....Pages 301-304
